Southern, your posts clearly indicate knowledge and experience with biotechs, and are infinitely more informative than what I can offer. I strongly believe you are underestimating the Clinuvel team and the strategy they have layed out. The meticulous (to the point of nauseam) nature of their trials and analysis will pave the way to approval with the EMA. The timing of this will avoid dilution. The approval itself will simply crack the door on the availability of this drug, which Phillipe & co. will kick in with expediated Vitiligo trials, introduction of 9900 and pediatric trials and the inevitable off label use. All of this will lead to a multibillion dollar company in 3 years or so. Use charts and your experience if you like, but timing this game is foolish. The odds of making 20 times your money by 2016 are no better any where else, so wait and be rewarded.
- Forums
- ASX - By Stock
- CUV
- nomura "maa review should complete by start 4q
nomura "maa review should complete by start 4q, page-7
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M |
Open | High | Low | Value | Volume |
$13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 227 | $13.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.42 | 228 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 227 | 13.280 |
1 | 228 | 13.270 |
2 | 398 | 13.260 |
5 | 3137 | 13.250 |
2 | 238 | 13.240 |
Price($) | Vol. | No. |
---|---|---|
13.420 | 228 | 1 |
13.440 | 228 | 1 |
13.450 | 228 | 1 |
13.460 | 228 | 1 |
13.500 | 800 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online